Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)

Autoři	HERTL M. JEDLIČKOVÁ Hana KARPATI S. MARINOVIC B. UZUN S. YAYLI S. MIMOUNI D. BORRADORI L. FELICIANI C. IOANNIDES D. JOLY P. KOWALEWSKI C. ZAMBRUNO G. ZILLIKENS D. JONKMAN M.F.
Rok publikování	2015
Druh	Článek v odborném periodiku
Časopis / Zdroj	Journal of the European Academy of Dermatology and Venereology
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1111/jdv.12772
Obor	Ostatní lékařské obory
Klíčová slova	DOUBLE-BLIND TRIAL; MYCOPHENOLATE-MOFETIL; CLINICAL-TRIAL; SPARING AGENT; PULSE THERAPY; VULGARIS; RITUXIMAB; DEXAMETHASONE; AZATHIOPRINE; PLACEBO
Popis	Background: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, the prognosis of pemphigus was almost fatal. Due to its rarity, only few prospective controlled therapeutic trials are available. Objectives:For this reason, a group of European dermatologists with a long-standing interest and expertise in basic and clinical pemphigus research has sought to define diagnostic and therapeutic guidelines for the management of patients with pemphigus. Results:This group identified the statements of major agreement or disagreement regarding the diagnostic and therapeutic management of pemphigus. The revised final version of the pemphigus guideline was finally passed on to the European Dermatology Forum (EDF) for a final consensus with the European Academy of Dermatology and Venereology (EADV) and the European Union of Medical Specialists (UEMS).